ESC 365 - Update on RNAi therapy in hATTR amyloidosis.

Open Access

Update on RNAi therapy in hATTR amyloidosis.

Session: New targets to enhance survival and outcomes in hATTR amyloidosis

Topic: Clinical

Speaker: Doctor P. Garcia-Pavia (Majadahonda, ES)

Sponsored by Alnylam Pharmaceuticals

Event: Heart Failure 2022

Congress Presentation

Add to my library

About the speaker

Doctor Pablo Garcia-Pavia

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)

62 presentations

15 followers

3 more presentations in this session

Welcome and introduction: the origin and evolution of the disease.

Speaker: Professor T. Damy (Creteil, FR)

Treatment strategies targeting TTR amyloid in hATTR amyloidosis (a multi-system disease).

Speaker: Doctor H. Nienhuis (Groningen, NL)

Discussion and closing remarks.

Speaker: Professor T. Damy (Creteil, FR) Doctor H. Nienhuis (Groningen, NL) Doctor P. Garcia-Pavia (Majadahonda, ES)

Access the full session

New targets to enhance survival and outcomes in hATTR amyloidosis

Speakers: Doctor P. Garcia-Pavia, Professor T. Damy, Doctor H. Nienhuis, Professor T. Damy, Doctor H. Nienhuis...

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources